drugset / Trial / NCT02796105

Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors

NCT02796105

Phase 4 Completed 232 enrolled Eugin
RandomizedParallel-groupOpen-labelOther

Summary

Evaluation of efficacy and safety of medroxiprogesterone acetate (Progevera 10 mg®) versus GnRh antagonist (Orgalutran®) in ovarian stimulation cycles of oocyte donors

Timeline

Start
2016-06
Primary completion
2017-07
Completion
2017-07-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ganirelix Protein / enzyme biologic 0.25 mg
Subject Progevera Unknown 10 mg Oral

Indications